ADCT

ADC Therapeutics SA

NYSEAdd to watchlist

Healthcare · Biotechnology

$1.05

−$0.01−0.94%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

1 open-market sale on file ($19.64M), none of them under a pre-arranged plan. Who, and when

Aug 24, 2026$1.05

+$0.08+8.80%over 1M

Session

Day range0% of range

$1.05$1.15

Fundamentals

Visualize fundamentals and more

Market cap: 162.77M
P/E ratio: -

Revenue grew +14.85% in FY2025, +5.98% faster than its sector. The median across Healthcare companies this platform tracks is +8.87%.

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 60
dropped: 46
re-drafted: 46

Out of 213 passages in this year’s Item 1A.

New this year

• Our partners may not perform as expected, and we may be unable to maintain existing or establish additional collaborations for the development and commercialization of our products and product candidates.

105 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Litigation
Product recalls
Debt covenants
Data privacy
Labour
Going concern

And 18 more.

FDA approval
Risks Related to Research and Development We may be unable to complete clinical trials on our expected timelines, if at all. Clinical trials are subject to the numerous risks described in this “Item 1A. Risk Factors” section and in our other filings with the …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

22 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

ADC Therapeutics SA investor relations

What ADCT has filed with the SEC. This is not ADC Therapeutics SA’s own investor relations site: these filings are the primary source that site publishes from.

Companies like ADC Therapeutics SA

Also filed under Biotechnology, ranked by how closely they sit beside ADCT.

MRNAModerna, Inc.compare with ADCT
ROIVRoivant Sciences Ltd.compare with ADCT
VRTXVertex Pharmaceuticals Inc. / MA

XENEXenon Pharmaceuticals Inc.compare with ADCT

NVONovo Nordisk A Scompare with ADCT

ADCT is among the largest companies matching:

gross margin above 70% and still lossmaking

Ask about ADC Therapeutics SA

The assistant answers from what ADCT has actually filed: 4 annual reports filed with the SEC, 39 Form 4 filings from the last year and 1 fund that holds it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from ADCT's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of ADC Therapeutics SA each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with ADC Therapeutics SA

Be told the moment a ADCT insider trades
Put ADC Therapeutics SA on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
ADC Therapeutics SA's income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about ADC Therapeutics SA's fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Litigation
Product recalls
Debt covenants
Data privacy
Labour
Going concern

And 18 more.

FDA approval
Risks Related to Research and Development We may be unable to complete clinical trials on our expected timelines, if at all. Clinical trials are subject to the numerous risks described in this “Item 1A. Risk Factors” section and in our other filings with the …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 60
dropped: 46
re-drafted: 46

Out of 213 passages in this year’s Item 1A.

New this year

• Our partners may not perform as expected, and we may be unable to maintain existing or establish additional collaborations for the development and commercialization of our products and product candidates.

105 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add